- CytomX press release ( NASDAQ: CTMX ): Q2 GAAP EPS of -$0.37 misses by $0.02 .
- Revenue of $18.17M (+11.5% Y/Y) misses by $0.21M .
For further details see:
CytomX GAAP EPS of -$0.37 misses by $0.02, revenue of $18.17M misses by $0.21MFor further details see:
CytomX GAAP EPS of -$0.37 misses by $0.02, revenue of $18.17M misses by $0.21MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...